Trial reportFuture oncology (London, England)2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Trial report in Future oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Efficacy of presurgical therapy with tislelizumab and axitinib to downsize local lesions in locally advanced and metastatic renal cell carcinoma: a single-institution experience with long-term follow-up.Translational andrology and urology · 2025Article
- Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?Biomedicines · 2025Review
- Sensitivity of renal cell carcinoma to cuproptosis: a bioinformatics analysis and experimental verification.Journal of Cancer · 2025Article
- Review
- Perioperative systemic therapy in high-risk renal cell carcinoma following nephrectomy: a narrative review.Translational cancer research · 2024Review
- Predictors of disease recurrence in high-risk non-metastatic renal cell carcinoma patients post-surgical resection A single-center, retrospective study.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
- NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial.Contemporary clinical trials communications · 2023Article
- ARHGAP11A Is a Novel Prognostic and Predictive Biomarker Correlated with Immunosuppressive Microenvironment in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2023Article
- PD-L1: expression regulation.Blood science (Baltimore, Md.) · 2023Review
- Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation.Journal of kidney cancer and VHL · 2023Article
- Kidney Cancer Research Highlights from ASCO GU 2022 Meeting.Kidney cancer journal : official journal of the Kidney Cancer Association · 2022Article
- Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.European urology oncology · 2022Article
- Adjuvant therapy for renal cell carcinoma, finally a new standard?Frontiers in oncology · 2022Article
- Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.Cancer science · 2022Article
- Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical OutcomeFrontiers in immunology · 2022Article
- Role of metastasectomy in the management of renal cell carcinoma.Frontiers in surgery · 2022Review
- Review
- A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.Urologic oncology · 2021Review
- Mapping the immune environment in clear cell renal carcinoma by single-cell genomics.Communications biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
Patients with high-risk renal cell carcinoma (RCC) experience high rates of recurrence despite definitive surgical resection. Recent trials of adjuvant tyrosine kinase inhibitor therapy have provided conflicting efficacy results at the cost of significant adverse events. PD-1 blockade via monoclonal antibodies has emerged as an effective disease-modifying treatment for metastatic RCC. There is emerging data across other solid tumors of the potential efficacy of neoadjuvant PD-1 blockade, and preclinical evidence supporting a neoadjuvant over adjuvant approach. PROSPER RCC is a Phase III, randomized trial evaluating whether perioperative nivolumab increases recurrence-free survival in patients with high-risk RCC undergoing nephrectomy. The neoadjuvant component, intended to prime the immune system for enhanced efficacy, distinguishes PROSPER from other purely adjuvant studies and permits highly clinically relevant translational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.